AbbVie Inc. $ABBV Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp trimmed its stake in AbbVie by 2.9%, selling 32,249 shares and now holds 1,092,161 shares valued at about $249.55 million (≈0.06% of AbbVie; AbbVie is ~0.6% of the firm's portfolio), while institutional ownership stands near 70.23%.
• Q4 results beat expectations: AbbVie reported EPS of $2.71 vs. $2.65 consensus and revenue of $16.62B (up 10% YoY), set FY2026 guidance of 14.370–14.570 EPS, and declared a quarterly dividend of $1.73 (3.5% yield) with a high payout ratio (~293%).
• Significant insider selling occurred (EVP Perry Siatis sold 22,381 shares for about $5.15M; SVP David Purdue sold 5,230 shares for about $1.22M), while analysts' consensus remains a "Moderate Buy" with an average price target of $253.19 and several firms issuing buy/overweight ratings.

Mitsubishi UFJ Trust & Banking Corp trimmed its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,092,161 shares of the company's stock after selling 32,249 shares during the quarter. AbbVie accounts for approximately 0.6% of Mitsubishi UFJ Trust & Banking Corp's portfolio, making the stock its 27th largest holding. Mitsubishi UFJ Trust & Banking Corp owned about 0.06% of AbbVie worth $249,552,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Eagle Wealth Advisors LLC purchased a new stake in AbbVie during the fourth quarter worth about $263,000. FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its holdings in AbbVie by 16.6% during the fourth quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 7,029 shares of the company's stock worth $1,606,000 after buying an additional 1,002 shares in the last quarter. Anchyra Partners LLC purchased a new stake in AbbVie during the fourth quarter worth about $1,155,000. First National Bank & Trust Co. of Newtown boosted its holdings in AbbVie by 2.1% during the fourth quarter. First National Bank & Trust Co. of Newtown now owns 11,766 shares of the company's stock worth $2,688,000 after buying an additional 239 shares in the last quarter. Finally, Aprio Wealth Management LLC boosted its holdings in AbbVie by 75.5% during the fourth quarter. Aprio Wealth Management LLC now owns 10,464 shares of the company's stock worth $2,391,000 after buying an additional 4,502 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

Shares of NYSE ABBV opened at $197.24 on Tuesday. AbbVie Inc. has a 12-month low of $176.57 and a 12-month high of $244.81. The company has a market capitalization of $348.76 billion, a PE ratio of 83.58, a price-to-earnings-growth ratio of 0.71 and a beta of 0.38. The firm's 50-day moving average is $215.99 and its two-hundred day moving average is $222.03.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the firm earned $2.16 earnings per share. The company's revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.5%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is 293.22%.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Barclays assumed coverage on shares of AbbVie in a report on Thursday, February 19th. They set an "overweight" rating and a $275.00 price objective on the stock. Weiss Ratings reissued a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. BMO Capital Markets reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. William Blair reissued an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Finally, Guggenheim boosted their price objective on shares of AbbVie from $242.00 to $249.00 and gave the stock a "buy" rating in a report on Friday, April 10th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $253.19.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie plans a $1B+ research campus in the Research Triangle, signaling long-term investment in R&D capacity and local life‑sciences ecosystem strength, which supports future growth and talent access. AbbVie's Planned $1B-Plus Research Triangle Campus Development Buoys Improved Life Sciences Outlook
• Positive Sentiment: AbbVie filed to expand SKYRIZI (risankizumab-rzaa) to subcutaneous induction for Crohn’s disease (supported by Phase 3 AFFIRM data) — a potential label expansion that could bolster revenue and diversify administration options. AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction
• Positive Sentiment: Analyst/retail commentary highlights AbbVie’s strong dividend profile and cash flow generation from core drugs, supporting the company’s ability to sustain payouts and buybacks. This underpins investor income expectations. AbbVie (ABBV) Maintains Dividend Strength as Core Drugs Drive Cash Flow
• Neutral Sentiment: Earnings season: previews and analyst notes flag AbbVie among big pharmas reporting this week — the Q1 print and management commentary will likely drive near‑term moves (expect volatility around results). AbbVie (ABBV) to report earnings tomorrow: Here is what to expect
• Neutral Sentiment: Sector preview pieces list AbbVie among drug majors under the microscope for Q1 — consensus expectations and EPS beats/misses across peers could influence sentiment. Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
• Negative Sentiment: AbbVie received a Complete Response Letter (CRL) from the FDA for its trenibotulinumtoxinE BLA — the CRL cites manufacturing issues tied to a wrinkle treatment, a near-term regulatory setback that creates uncertainty for that program and potential revenue. AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE FDA rejects AbbVie wrinkle treatment application over manufacturing issues
• Negative Sentiment: New competitive data from a small biotech (Oruka Therapeutics) shows high clearance rates for a psoriasis candidate, which could pressure AbbVie’s large dermatology franchise if follow‑on data and approvals materialize. How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.06% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.